CJA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a scholarly reply
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by FLEMING, S. A.
Right arrow Articles by ROBINSON, J. G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by FLEMING, S. A.
Right arrow Articles by ROBINSON, J. G.

Canadian Journal of Anesthesia, Vol 4, 52-54, Copyright © 1957 by Canadian Anesthesiologists' Society

Neraval® Sodium: A Clinical Investigation

SHIRLEY A. FLEMING M.D., F.F.A.R.C.S.1 and J. G. ROBINSON M.D.1

1 Department of Anaesthesia, University of Toronto, and Toronto General Hospital

Eighty patients were anaesthetized with Neraval Sodium, 35 of whom received no other anaesthetic agent. In the remainder of cases the procedures were more major neurological, orthopaedic, gynaecological, abdominal, ear, nose and throat or eye operations and these patients received Neraval for induction and in some cases intermittently throughout the operation, as well as other agents for maintenance.

The conclusion reached was that the drug is similar to the commonly used ultra short-acting barbiturates in its action but that the drug exerts a parasympathetic action as manifested by hiccoughing, coughing, retching and laryngospasm in an appreciable number of patients. It could not be demonstrated in this series that Neraval was the shortest acting of the ultra short-acting barbiturates.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1957 by the Canadian Anesthesiologists' Society.